Financing type:  bought deal prospectus offering

Gross proceeds:  $34,500,690

Offering:  32,857,800 common listed shares with 16,428,900 warrants

Offering price:  $1.05 per common listed share

Warrant exercise terms:  $1.40 per common listed share for a three-year period

Overallotment option:  The agents may purchase a maximum of 4,285,800 common listed shares and 2,142,900 warrants for overallotment purposes. As of Jan. 20, 2026, such option has expired and 4,285,800 common listed shares and 2,142,900 warrants have been issued thereunder. All information presented herein includes such exercise.

Commissions in securities:  1,970,887 finders' warrants

Commission terms:  Each non-transferable warrant is exercisable at $1.05 for a three-year period.

Disclosure:  Refer to the short form base shelf prospectus dated Nov. 26, 2025, and the prospectus supplement dated Jan. 2, 2026, and the company's news releases dated Dec. 30, 2025, Dec. 31, 2025, and Jan. 14, 2026.